ASH 2023 | Dual-targeting CD33/CD123 NANOBODY® T cell engager in relapsed AML
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses a study using immunophenotypic profiling to assess the target engagement of a novel dual-targeting CD33/CD123 NANOBODY® T-cell engager with acute myeloid leukemia (AML) blasts and leukemic stem cells. The findings demonstrate the successful elimination of target cells, suggesting the potential of dual-targeting immune engagers as a treatment option for AML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So this is a pre-clinical work from my laboratory exploiting the novel CD123 T-cell engager using not the traditional antibody, but a nanobody, so it’s a different version of using this type of engager. So we’ve done pre-clinical work in primary AML that express CD123. We showed that the majority of the primary AML express high levels of CD123, including on the level of leukemia stem cells...
So this is a pre-clinical work from my laboratory exploiting the novel CD123 T-cell engager using not the traditional antibody, but a nanobody, so it’s a different version of using this type of engager. So we’ve done pre-clinical work in primary AML that express CD123. We showed that the majority of the primary AML express high levels of CD123, including on the level of leukemia stem cells. And when we combine the T-cells with the blasts and this T-cell engager, we showed quite high efficacy in the in vitro models, also including the clonogenic assays, and also using the multiparametric cyto flow cytometry, we showed elimination of some of the stem cell pools. So this is a challenging area in AML because so far the T-cell engagers have not shown as much efficacy, mainly because of the issues of cytokine release syndrome. So the question is whether this particular agent will be different from what has been tried and I don’t really have an answer to that, but I think that’s one way of sort of going forward and trying to explore the efficacy of that. This was pre-clinical work.
Read more...
Disclosures
Current holder of stock options: Reata Pharmaceuticals
Patents & Royalties: Reata Pharmaceuticals
Consultancy: AbbVie, AstraZeneca, Genentech, Gilead, Janssen, MEI Pharma, Sanofi Aventis, Stemline-Menarini, Vincerx
Research Funding: AbbVie, Ablynx, Allogene, AstraZeneca, Cellectis, Daiichi, FortySeven, Genentech, Gilead, Immunogen, MEI Pharma, Precision Biosciences, Rafael Pharmaceutical, Sanofi Aventis, Stemline-Menarini
